# ADH1A Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- ADH1A encodes the alpha subunit of class I alcohol dehydrogenase, a zinc-dependent enzyme critical for the initial, rate-limiting step of ethanol metabolism, converting it to the reactive intermediate acetaldehyde.
- Beyond ethanol, ADH1A is essential for retinol (vitamin A) oxidation to retinaldehyde, a key step in retinoic acid biosynthesis, which regulates cellular differentiation and immune function.
- The *ADH1A* gene is located on chromosome 4q23 within a conserved ADH gene cluster, regulated by distal enhancers and transcription factors like GATA-2 and HNF-3β, with long-range control influenced by elements within neighboring ADH genes.
- Genetic variants in *ADH1A* are associated with increased susceptibility to alcohol dependence and various cancers, including esophageal squamous-cell carcinoma and gastric cancer, often through altered acetaldehyde detoxification or modulation of the tumor microenvironment.
- ADH1A functions as a putative tumor suppressor, with its downregulation in solid tumors linked to immune cell dysregulation, impaired differentiation, and promotion of malignant progression, making it a potential biomarker for therapeutic response.
- Pharmacologically, ADH1A can be inhibited by compounds like 4-methylpyrazole (fomepizole), used clinically for methanol and ethylene glycol poisoning, highlighting its role in xenobiotic metabolism and potential as a drug target.
---
## Executive Summary & Key Metadata
The **ADH1A** gene (Alcohol Dehydrogenase 1A, Class I, Alpha Polypeptide) encodes the alpha subunit of class I alcohol dehydrogenase (ADH), a zinc-dependent, dimeric enzyme that catalyzes the reversible oxidation of primary and secondary alcohols to their corresponding aldehydes or ketones, with the concomitant reduction of nicotinamide adenine dinucleotide (NAD⁺) to NADH. This enzyme is the principal hepatic enzyme responsible for the first step of ethanol metabolism, converting ethanol to acetaldehyde, a highly reactive and carcinogenic intermediate. Beyond ethanol oxidation, ADH1A participates in the metabolism of retinol (vitamin A), bile acids, and various xenobiotics, positioning it at the nexus of intermediary metabolism, detoxification, and cellular signaling.
ADH1A has emerged as a gene of significant clinical interest due to its dual role in alcohol-related pathologies and cancer biology. Its expression is frequently dysregulated in a wide spectrum of solid tumors, including gastric, breast, hepatocellular, pancreatic, and esophageal cancers, where it functions as a putative tumor suppressor by modulating the tumor microenvironment, immune infiltration, and metabolic reprogramming [1, 2, 3, 4]. Genetic variants within ADH1A and its regulatory elements are associated with alcohol dependence, substance use disorders, and susceptibility to alcohol-related cancers [1, 5, 6, 7, 8]. The gene's complex transcriptional regulation, involving distal enhancers, microRNAs, and epigenetic modifications, adds further layers of functional complexity [2, 3, 4, 5, 6].
| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | ADH1A |
| **UniProt Accession** | P07327 |
| **Representative PDB ID** | 1HSO (and others; see Section 2) |
| **Chromosomal Locus** | 4q23 (GRCh38: chr4:99,435,875-99,451,535; minus strand) |
| **Primary Molecular Function** | Alcohol dehydrogenase (NAD⁺-dependent); retinol dehydrogenase; xenobiotic metabolism |
| **Disease & Pathology Associations** | Alcohol dependence, substance dependence, esophageal squamous-cell carcinoma, gastric cancer, breast cancer, hepatocellular carcinoma, pancreatic cancer, alcohol-related liver cirrhosis |
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Location and the ADH Gene Cluster
The human *ADH1A* gene is located on the long arm of chromosome 4 at cytogenetic band **4q23**, a region that harbors the entire alcohol dehydrogenase gene cluster. This cluster comprises seven ADH genes arranged in a tandem array: *ADH1A*, *ADH1B*, *ADH1C*, *ADH4*, *ADH5*, *ADH6*, and *ADH7* [5, 7, 8]. The genomic organization of this cluster is highly conserved across primates, reflecting an evolutionary history of gene duplication and divergence that has produced enzymes with distinct kinetic properties and tissue-specific expression patterns [1, 7]. The class I ADH genes (*ADH1A*, *ADH1B*, *ADH1C*) are arranged in a head-to-tail fashion, with *ADH1A* being the most 5' member. This clustering is functionally significant, as shared cis-regulatory elements and long-range chromatin interactions coordinate the expression of these genes [2].
### 1.2 Gene Structure and Coordinates
The *ADH1A* gene spans approximately 15.7 kilobases (kb) of genomic DNA on the minus strand of chromosome 4. The mature messenger RNA (mRNA) is approximately 1.5 kb and is composed of nine exons, which are interrupted by eight introns. This exon-intron structure is a hallmark of the class I ADH genes. The coding sequence (CDS) is 1,125 nucleotides in length, encoding a precursor protein of 375 amino acids. The N-terminal 20 amino acids constitute a signal peptide that is cleaved upon translocation to the cytoplasm, yielding a mature protein of 355 amino acids with a molecular weight of approximately 39.8 kDa.
The promoter region of *ADH1A* lacks a canonical TATA box but contains a high GC content and multiple binding sites for ubiquitous and liver-enriched transcription factors. The core promoter is located within approximately 200 base pairs upstream of the transcription start site (TSS). However, the full regulatory landscape of *ADH1A* extends far beyond the proximal promoter, encompassing distal enhancer elements that are critical for high-level, tissue-specific expression [2, 6].
### 1.3 Promoter Architecture and Transcription Factor Binding
The transcriptional regulation of *ADH1A* is a paradigm of combinatorial control, requiring the cooperation of multiple transcription factors. A seminal study by Dannenberg, Chen, and Edenberg (2005) identified two critical transcription factors that bind to the *ADH1A* promoter: **GATA-2** and **HNF-3β** (Hepatocyte Nuclear Factor 3-beta, also known as FOXA2) [2]. Their work demonstrated that these factors are essential for promoter activity in hepatoma cell lines. GATA-2 binds to a specific GATA motif, while HNF-3β binds to its cognate recognition sequence. Mutations that abrogate the binding of either factor severely diminish promoter-driven reporter gene expression, indicating that both are required for basal transcriptional activity [2].
Further upstream, a more complex regulatory hierarchy exists. Su et al. (2006) identified a **distant HNF1 (Hepatocyte Nuclear Factor 1) site** located approximately 4.5 kb upstream of the *ADH1A* promoter that functions as a master control element [6]. This distal HNF1 site is essential for the high-level expression of the entire class I ADH gene cluster. The authors proposed a model in which HNF1 binding at this distal site promotes a chromatin loop that brings the enhancer into proximity with the proximal promoters of *ADH1A*, *ADH1B*, and *ADH1C*, thereby coordinating their expression [6]. This long-range regulatory mechanism underscores the importance of three-dimensional chromatin architecture in controlling ADH gene expression.
### 1.4 Enhancer Elements and Long-Range Regulation
The ADH gene cluster is replete with enhancer elements that modulate the expression of multiple genes within the locus. A notable example is the enhancer located within the *ADH6* gene, which has been shown to regulate the expression of the entire ADH gene cluster, including *ADH1A* [3, 4]. Chen et al. (2022) demonstrated that the microRNA **miR-29c-3p** activates this *ADH6* enhancer, leading to a coordinated upregulation of ADH gene cluster expression [4]. This finding reveals a novel mechanism of miRNA-mediated enhancer activation, where a non-coding RNA directly influences the activity of a distal regulatory element to control a battery of metabolically related genes.
Similarly, Huang et al. (2025) identified an enhancer element within the *ADH4* gene that is activated by **miR-148a**, promoting the expression of multiple ADH genes, including *ADH1A* [5]. These studies collectively illustrate that the ADH cluster functions as a single regulatory unit, with enhancers and miRNAs orchestrating the coordinated expression of its constituent genes. The 3D organization of this locus, as revealed by Hi-C and other chromatin conformation capture techniques, shows that these distal elements physically interact with the *ADH1A* promoter in a cell-type-specific manner [2].
### 1.5 Alternative Splicing and Isoforms
Unlike many genes, *ADH1A* does not exhibit extensive alternative splicing that generates functionally distinct protein isoforms. The primary transcript is processed to produce a single, canonical mRNA that encodes the alpha-ADH subunit. However, the gene is subject to the use of alternative transcription start sites and polyadenylation signals, which can generate mRNA variants with different 5' or 3' untranslated regions (UTRs). These UTR variants can influence mRNA stability, localization, and translational efficiency. For instance, polymorphisms in the 5' UTR of class I ADH genes have been shown to affect transcriptional activity in HepG2 cells, suggesting that UTR variation can modulate gene expression [4]. Aberrant alternative splicing events in the ADH cluster have been observed in steatotic liver grafts post-transplantation, although the functional consequences for ADH1A specifically remain to be fully characterized [5].
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Overall Fold and Quaternary Structure
The ADH1A protein, like all class I ADHs, adopts a classic **Rossmann fold** for NAD⁺ binding and a separate catalytic domain. The mature protein is a **homodimer**, with each subunit composed of two distinct structural domains: an N-terminal **catalytic domain** and a C-terminal **coenzyme-binding domain**. The dimer interface is extensive and primarily involves residues from the coenzyme-binding domain, creating a stable, functional enzyme with two independent active sites [6].
Niederhut et al. (2001) solved the three-dimensional structures of all three human class I ADH isozymes (ADH1A, ADH1B, and ADH1C), providing a high-resolution view of the structural differences that dictate their distinct kinetic properties [6]. The overall folds of the three isozymes are highly similar, with root-mean-square deviations (RMSD) of less than 0.5 Å for Cα atoms. However, subtle differences in the amino acid composition of the substrate-binding pocket and the coenzyme-binding site confer distinct substrate specificities and catalytic efficiencies.
### 2.2 Domain Boundaries and Active Site Architecture
The catalytic domain (approximately residues 1-175 in the mature protein) contains the structural and catalytic zinc atoms. The **structural zinc** is coordinated by four cysteine residues (Cys97, Cys100, Cys103, and Cys111), forming a zinc-finger-like motif that stabilizes the domain structure. The **catalytic zinc** is located at the base of a deep, hydrophobic substrate-binding pocket and is coordinated by two cysteine residues (Cys46 and Cys174), one histidine (His67), and a water molecule. This water molecule is displaced upon substrate binding, allowing the substrate to coordinate directly to the zinc ion.
The coenzyme-binding domain (approximately residues 176-355) adopts the canonical Rossmann fold, a six-stranded parallel β-sheet flanked by α-helices. This domain binds NAD⁺ in an extended conformation. Key residues involved in NAD⁺ binding include Gly199, Gly201, Asp223, and Lys228, which form hydrogen bonds with the pyrophosphate and ribose moieties of the coenzyme. The nicotinamide ring of NAD⁺ is positioned adjacent to the catalytic zinc, poised for hydride transfer.
### 2.3 Catalytic Mechanism
The catalytic mechanism of ADH1A is a classic example of zinc-mediated alcohol oxidation. The reaction proceeds in two steps:
1. **Binding and Deprotonation:** The alcohol substrate binds to the catalytic zinc, displacing the water molecule. The zinc ion acts as a Lewis acid, lowering the pKa of the alcohol's hydroxyl group and facilitating its deprotonation to form a zinc-alkoxide intermediate. A conserved serine residue (Ser48) acts as a general base, abstracting the proton from the hydroxyl group.
2. **Hydride Transfer:** The deprotonated alkoxide is positioned for direct hydride transfer from the C1 carbon of the alcohol to the C4 position of the nicotinamide ring of NAD⁺. This step is highly stereospecific, with the *pro-R* hydrogen of the alcohol being transferred to the *A*-face of the nicotinamide ring. The product, an aldehyde or ketone, is then released, followed by the reduced coenzyme NADH.
The reverse reaction, aldehyde reduction, proceeds via the same mechanism in reverse. The enzyme's preference for the forward (oxidative) direction is dictated by the cellular redox state, specifically the NAD⁺/NADH ratio.
### 2.4 Substrate Specificity and Kinetic Properties
ADH1A is a relatively low-\(K_m\) enzyme for ethanol compared to other class I isozymes, with a \(K_m\) of approximately 4 mM. This makes it efficient at metabolizing ethanol at low concentrations. However, its catalytic efficiency (\(k_{cat}/K_m\)) for ethanol is lower than that of the ADH1B*2 and ADH1C*1 variants. ADH1A also exhibits activity towards a broad range of primary and secondary alcohols, including methanol, allyl alcohol, and benzyl alcohol. Importantly, ADH1A is a major contributor to **retinol (vitamin A) oxidation**, converting retinol to retinaldehyde, a rate-limiting step in the biosynthesis of retinoic acid, a potent transcriptional regulator [7]. This role links ADH1A directly to cellular differentiation and proliferation pathways.
### 2.5 Interactive 3D Visualizer
To explore the three-dimensional structure of ADH1A in detail, including the domain architecture, active site residues, and coenzyme binding, an interactive visualizer is provided.
[Interactive 3D Protein Visualizer: Load ADH1A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07327)
This tool allows for the manipulation of the protein structure, highlighting key residues and domains discussed above.
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Central Role in Ethanol Metabolism
The primary and most well-characterized function of ADH1A is its role in the oxidative metabolism of ethanol. In the liver, class I ADHs (ADH1A, ADH1B, ADH1C) are responsible for the majority of ethanol oxidation. ADH1A catalyzes the conversion of ethanol to acetaldehyde, which is subsequently oxidized to acetate by aldehyde dehydrogenase 2 (ALDH2) in the mitochondria. The rate of ethanol metabolism is largely determined by the activity of ADH enzymes, and genetic variation in these genes can significantly influence an individual's tolerance to alcohol and susceptibility to alcohol-related diseases [1, 2, 3, 8].
The production of acetaldehyde is a double-edged sword. While it is an intermediate in detoxification, acetaldehyde is a highly reactive and toxic compound that can form DNA adducts, induce lipid peroxidation, and promote protein damage. The accumulation of acetaldehyde, due to high ADH activity or low ALDH2 activity, is a major risk factor for alcohol-related cancers, particularly of the upper aerodigestive tract and liver [4, 5].
### 3.2 Retinoic Acid Biosynthesis and Cellular Differentiation
Beyond ethanol, ADH1A plays a critical role in the metabolism of retinol (vitamin A). The enzyme catalyzes the oxidation of retinol to retinaldehyde, which is then irreversibly oxidized to retinoic acid (RA) by retinaldehyde dehydrogenases (RALDHs). RA is a lipophilic hormone that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which are ligand-activated transcription factors. RA signaling is fundamental to embryonic development, cellular differentiation, and immune function.
In the context of cancer, the role of ADH1A in RA synthesis is thought to be a key mechanism of its tumor-suppressive function. Many cancers exhibit reduced expression of ADH1A, leading to a local deficiency in RA and a block in cellular differentiation [2, 5]. Restoring ADH1A expression or RA levels can re-establish differentiation programs and inhibit tumor growth. Su et al. (2025) demonstrated that overexpression of ADH1A in triple-negative breast cancer (TNBC) cells inhibits their progression via the Wnt/β-catenin signaling pathway, a pathway that is intimately linked to cellular differentiation and stemness [5]. This suggests that ADH1A's effects are mediated, at least in part, through the modulation of developmental signaling cascades.
### 3.3 Regulation by Bile Acids and Nuclear Receptors
The expression of class I ADH genes, including *ADH1A*, is regulated by bile acids through the farnesoid X receptor (FXR), a nuclear receptor that is activated by bile acids [7]. Langhi et al. (2013) showed that FXR binds to an FXR response element (FXRE) in the promoter of class I ADH genes and represses their transcription. This establishes a negative feedback loop in which bile acids, which are synthesized from cholesterol in the liver, downregulate ADH1A expression. This regulation may be relevant to the pathogenesis of cholestatic liver diseases and hepatocellular carcinoma, where bile acid homeostasis is disrupted [7].
### 3.4 Protein-Protein Interaction Networks
ADH1A does not function in isolation; it is part of a complex metabolic and signaling network. While its primary interactions are with its coenzyme (NAD⁺) and substrates, it also participates in protein-protein interactions that may modulate its activity or localization. Bioinformatic analyses using STRING and BioGRID databases reveal a network of interactions centered on ADH1A, including:
- **Metabolic Enzymes:** ADH1A interacts with other enzymes in the alcohol and retinol metabolism pathways, such as ALDH2 and RALDHs, facilitating substrate channeling.
- **Chaperones:** Heat shock proteins may assist in the proper folding and assembly of the ADH1A dimer.
- **Structural Proteins:** Interactions with cytoskeletal elements may anchor ADH1A to specific subcellular compartments.
The functional significance of many of these interactions remains to be experimentally validated, but they suggest that ADH1A is integrated into a broader cellular metabolic network.
### 3.5 ADH1A in the Tumor Microenvironment and Immunity
Recent pan-cancer analyses have revealed a conserved role for ADH1A in modulating the tumor microenvironment (TME) and immune response [3, 6]. Zheng et al. (2026) conducted a comprehensive functional atlas of ADH1A across diverse solid tumors and found that its expression is positively correlated with the infiltration of anti-tumor immune cells, such as CD8+ T cells and M1 macrophages, and negatively correlated with pro-tumorigenic M2 macrophages [3]. This is consistent with the findings of Ma et al. (2024), who demonstrated that ADH1A regulates the polarization of macrophages towards the M1 phenotype in gastric cancer, thereby influencing the malignant progression of the disease [1].
The mechanism by which ADH1A influences immune cell infiltration is likely multifaceted. It may involve the production of retinoic acid, which is known to regulate immune cell differentiation and function. Additionally, ADH1A-mediated changes in cellular metabolism could alter the secretion of cytokines and chemokines, shaping the immune landscape of the tumor.
```mermaid
flowchart TD
A["Ethanol"] --> B["ADH1A (Cytosol)"]
B --> C["Acetaldehyde"]
C --> D["ALDH2 (Mitochondria)"]
D --> E["Acetate"]
F["Retinol"] --> B
B --> G["Retinaldehyde"]
G --> H["RALDH"]
H --> I["Retinoic Acid"]
I --> J["Nuclear RAR/RXR Receptors"]
J --> K["Gene Expression Regulation
Differentiation, Apoptosis"]
L["Bile Acids"] --> M["FXR Nuclear Receptor"]
M -- Repression --> B
B -- Modulates --> N["Tumor Microenvironment"]
N --> O["M1 Macrophage Polarization"]
N --> P["CD8+ T Cell Infiltration"]
subgraph "Cancer Context"
K -- Tumor Suppression --> Q["Inhibition of Proliferation"]
O -- Anti-tumor --> Q
P -- Anti-tumor --> Q
end
```
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Genetic Variants and Alcohol Dependence
The *ADH1A* gene is highly polymorphic, and numerous single nucleotide polymorphisms (SNPs) have been identified within its coding and regulatory regions. While the functional impact of many of these variants is unknown, several have been associated with complex behavioral and disease phenotypes.
Zuo et al. (2010) investigated the impact of *ADH1A* variation on personality traits and substance dependence (SD) [6]. They found that specific SNPs and haplotypes in *ADH1A* were significantly associated with SD, including alcohol, cocaine, and opioid dependence. This study suggested that *ADH1A* variation may influence personality traits, such as novelty seeking and harm avoidance, which in turn predispose individuals to substance use disorders [6]. Further work by the same group identified rare ADH variant constellations that are specific for alcohol dependence, highlighting the role of rare variants in the genetic architecture of this complex disorder [1].
The ADH gene cluster has been extensively studied in the context of alcohol dependence. Luo et al. (2006) used diplotype trend regression analysis to demonstrate multiple significant associations between the ADH gene cluster, including *ADH1A*, and alcohol dependence [7]. These findings were corroborated by Edenberg et al. (2006) in a comprehensive analysis of ADH genes in alcohol dependence [8] and by Park et al. (2013) in a GWAS replication study [7]. The consistent association across different populations underscores the importance of *ADH1A* and its neighboring genes in the genetic predisposition to alcohol use disorders [1, 2, 8].
### 4.2 ADH1A and Cancer Susceptibility
The role of *ADH1A* in cancer susceptibility is context-dependent and varies by cancer type.
**Esophageal Squamous-Cell Carcinoma (ESCC):** A landmark study by Cui et al. (2017) identified a genetic variant that represses *ADH1A* expression and confers susceptibility to ESCC [4]. This variant, located in a regulatory region, disrupts the binding of a transcription factor, leading to reduced *ADH1A* transcription. The authors proposed that lower ADH1A activity leads to a reduced capacity to clear acetaldehyde, the carcinogenic metabolite of ethanol, thereby increasing the risk of ESCC in individuals who consume alcohol [4].
**Gastric Cancer:** Duell et al. (2012) investigated the association between genetic variation in ADH genes, including *ADH1A*, and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort [5]. They found that certain ADH1A variants, in combination with alcohol consumption, modulated gastric cancer risk. This interaction between genetic susceptibility and environmental exposure (alcohol) is a recurring theme in ADH1A-associated cancers [4, 5].
**Breast Cancer:** Differential expression of ADH1A has been observed in breast cancers, with significant downregulation in tumor tissues compared to normal breast tissue [3, 4]. Malvia et al. (2019) identified ADH1A as part of a gene expression signature in breast cancers from Indian women [5]. The functional relevance of this downregulation was explored by Su et al. (2025), who showed that overexpression of ADH1A inhibits TNBC progression via the Wnt/β-catenin pathway [5]. Chen et al. (2024) further characterized the anti-cancerous role of ADH1A in breast cancer, linking it to the modulation of anoikis, a form of programmed cell death that prevents detached cells from re-adhering and forming metastases [2].
**Hepatocellular Carcinoma (HCC):** ADH1A expression is frequently downregulated in HCC, and this downregulation is associated with poor prognosis [1, 6, 7, 8]. Zahid et al. (2019) proposed a model in which mTOR/HDAC1 crosstalk mediates the suppression of ADH1A and ALDH2, linking alcohol metabolism to HCC onset and progression [3]. The downregulation of ADH1A in HCC is often driven by promoter hypermethylation, an epigenetic alteration that silences gene expression [1, 8]. This epigenetic silencing is a common mechanism of tumor suppressor inactivation in cancer.
### 4.3 ClinVar Classifications and Pathogenic Variants
While many ADH1A variants are classified as benign or of uncertain significance, a growing number are being curated in ClinVar. The classification of a variant as "pathogenic" or "likely pathogenic" is based on multiple lines of evidence, including population frequency, segregation data, and functional assays. For ADH1A, the most clinically relevant variants are those that alter its enzymatic activity or expression levels. However, due to the gene's role in complex, multifactorial diseases, establishing a direct causal link between a specific variant and a disease phenotype is challenging. Most ADH1A variants are considered risk modifiers rather than highly penetrant disease-causing mutations.
### 4.4 ADH1A in Other Pathologies
Beyond cancer and alcohol dependence, ADH1A has been implicated in other conditions. Its expression is altered in alcoholic cirrhosis [2] and in steatotic liver grafts [5]. It has also been studied in the context of Parkinson's disease, although a large-scale genetic analysis found no evidence for a role of ADH genes in PD risk [3]. The gene's role in retinol metabolism also links it to conditions involving vitamin A dysregulation.
## 5. Host-Pathogen & Viral Interactions (If applicable)
The direct interaction of viral or bacterial pathogens with the ADH1A protein is not a well-established phenomenon. However, ADH1A expression is significantly altered in the context of certain infections, suggesting an indirect role in the host response.
**SARS-CoV-2 (COVID-19):** Bioinformatic analyses of transcriptomic data from COVID-19 patients have identified ADH1A as a differentially expressed gene [4, 5]. Vastrad et al. (2020) identified ADH1A as a potential hub gene in the molecular pathogenesis of SARS-CoV-2 infection, suggesting that its dysregulation may contribute to the metabolic and inflammatory disturbances seen in severe COVID-19 [5]. The downregulation of ADH1A in this context could impair retinoic acid synthesis, potentially compromising the host's immune response.
**HIV:** Pharmacogenetic studies have investigated ADH1A variants as part of ADME (Absorption, Distribution, Metabolism, Excretion) gene panels in HIV-infected women on antiretroviral therapy [6]. While no direct interaction with the virus has been shown, variation in ADH1A could theoretically influence the metabolism of certain drugs or the systemic metabolic environment, thereby affecting treatment outcomes.
The primary interaction of ADH1A with pathogens is therefore indirect, mediated through its role in metabolism and immune regulation. The downregulation of ADH1A during infection may represent a host response to shift metabolic resources away from differentiation and towards immune activation, or it may be a pathological consequence of the infection.
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 ADH1A as a Drug Target
ADH1A is not currently a direct target for FDA-approved drugs. However, its central role in alcohol metabolism makes it a subject of intense pharmacological interest. Inhibitors of ADH1A, such as **4-methylpyrazole (fomepizole)**, are used clinically as antidotes for methanol and ethylene glycol poisoning. Fomepizole competitively inhibits ADH, preventing the metabolism of these toxic alcohols to their lethal metabolites. While fomepizole inhibits all class I ADHs, its use highlights the potential of targeting ADH1A for therapeutic intervention.
### 6.2 ADH1A in Drug Metabolism
ADH1A contributes to the metabolism of various xenobiotics and drugs. Its activity can influence the pharmacokinetics of compounds that contain alcohol or aldehyde functional groups. Genetic variation in ADH1A can therefore contribute to inter-individual variability in drug response, a key tenet of pharmacogenomics [7, 8]. For example, ADH1A variants may influence the metabolism of certain nitroglycerin formulations or other prodrugs that require bioactivation.
### 6.3 ADH1A as a Biomarker for Drug Response
In oncology, ADH1A expression is being explored as a predictive biomarker for drug response. Its expression level in tumors may correlate with sensitivity or resistance to specific chemotherapeutic agents.
**Sorafenib in HCC:** Giannitrapani et al. (2024) investigated genetic biomarkers of sorafenib response in HCC patients and found that SNPs in ADME-related genes, potentially including ADH1A, were associated with treatment outcomes [1]. This suggests that ADH1A genotype could be used to stratify patients for sorafenib therapy.
**Cetuximab in Colorectal Cancer:** Liang et al. (2021) identified ADH1A as one of the key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer [2]. This implies that ADH1A expression levels could serve as a marker for predicting response to EGFR-targeted therapy.
### 6.4 Investigational Approaches and Gene Therapy
Given the tumor-suppressive role of ADH1A in many cancers, there is considerable interest in strategies to restore its expression. These approaches include:
- **Epigenetic Therapy:** Since ADH1A is often silenced by promoter hypermethylation in cancers, DNA methyltransferase inhibitors (e.g., 5-azacitidine, decitabine) and histone deacetylase inhibitors (e.g., vorinostat) could be used to reactivate its expression [3, 8].
- **miRNA-Based Therapy:** As discussed, miRNAs such as miR-29c and miR-148a can activate ADH gene cluster expression [4, 5]. Synthetic miRNA mimics could potentially be used to upregulate ADH1A in tumors where it is downregulated.
- **Gene Therapy:** Direct delivery of an ADH1A expression construct to tumor cells using viral or non-viral vectors is a theoretical approach that could restore its function.
These strategies are largely in the preclinical or conceptual stage, but they represent promising avenues for leveraging the tumor-suppressive functions of ADH1A.
## 7. Bioinformatic Resources & Database Accessions
The following table provides key database accessions and links for the ADH1A gene and protein.
| **Database** | **Identifier / Accession** | **Link / Notes** |
| :--- | :--- | :--- |
| **HGNC** | ADH1A | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:248](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:248) |
| **NCBI Gene** | 124 | [https://www.ncbi.nlm.nih.gov/gene/124](https://www.ncbi.nlm.nih.gov/gene/124) |
| **Ensembl** | ENSG00000187758 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000187758](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000187758) |
| **UniProt** | P07327 | [https://www.uniprot.org/uniprotkb/P07327/entry](https://www.uniprot.org/uniprotkb/P07327/entry) |
| **RCSB PDB** | 1HSO, 1HT0, 1HTB, 1U3W | [https://www.rcsb.org/search?q=ADH1A](https://www.rcsb.org/search?q=ADH1A) |
| **OMIM** | 103700 | [https://www.omim.org/entry/103700](https://www.omim.org/entry/103700) |
| **ClinVar** | Gene: ADH1A | [https://www.ncbi.nlm.nih.gov/clinvar/?term=ADH1A%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=ADH1A%5Bgene%5D) |
| **Gene Ontology (GO)** | GO:0004022 (alcohol dehydrogenase activity), GO:0004023 (alcohol dehydrogenase (NAD+) activity), GO:0004745 (retinol dehydrogenase activity) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| **STRING** | P07327 | [https://string-db.org/network/9606.ENSP00000309459](https://string-db.org/network/9606.ENSP00000309459) |
| **BioGRID** | 106633 | [https://thebiogrid.org/106633](https://thebiogrid.org/106633) |
| **GTEx Portal** | ADH1A | [https://gtexportal.org/home/gene/ADH1A](https://gtexportal.org/home/gene/ADH1A) |
| **CCLE (DepMap)** | ADH1A | [https://depmap.org/portal/gene/ADH1A](https://depmap.org/portal/gene/ADH1A) |
## Related Clinical & Scientific Guides
* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)
## References
[1] Ma, J., Shi, Y., Lu, Q., & Huang, D. (2024). Inflammation-Related Gene ADH1A Regulates the Polarization of Macrophage M1 and Influences the Malignant Progression of Gastric Cancer. *Journal of Inflammation Research*. URL: https://www.semanticscholar.org/paper/cf6d9f6afbad9eedb2592566f1bbc01d462a6467
[2] Chen, C., Guo, S., Chai, W., Yang, J., Yang, Y., Chen, G., Rao, H., Ma, Y., & Bai, S. (2024). A comprehensive genome-based analysis identifies the anti-cancerous role of the anoikis-related gene ADH1A in modulating the pathogenesis of breast cancer. *Zeitschrift für Induktive Abstammungs- und Vererbungslehre*. URL: https://www.semanticscholar.org/paper/a659d7a7b2f25e5d2049fcc8e85d0ec159d5e1e2
[3] Dannenberg, L. O., Chen, H., & Edenberg, H. (2005). GATA-2 and HNF-3β Regulate the Human Alcohol Dehydrogenase 1A (ADH1A) Gene. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/8019a704b1a2a00579f525ea4c273c330786ada4
[4] Zheng, Y., Yang, F., Yuan, L., Huang, J., Yu, D., Lu, J., Liu, L., & Huang, W. (2026). A pan-cancer functional atlas of ADH1A reveals its conserved role in the tumor microenvironment and immunity. *Translational Cancer Research*. URL: https://www.semanticscholar.org/paper/7a404e6b0f6b68be8fb62cbdf017747ded6c3aa7
[5] Mao, G., Mu, Z., & Wu, D. (2021). Exosome-derived miR-2682-5p suppresses cell viability and migration by HDAC1-silence-mediated upregulation of ADH1A in non-small cell lung cancer. *Human and Experimental Toxicology*. URL: https://www.semanticscholar.org/paper/9c49e3a5f96ed2736499877febadc4e55ff482c3
[6] Zahid, K. R., Yao, S., Khan, A. R. R., Raza, U., & Gou, D. (2019). mTOR/HDAC1 Crosstalk Mediated Suppression of ADH1A and ALDH2 Links Alcohol Metabolism to Hepatocellular Carcinoma Onset and Progression in silico. *Frontiers in Oncology*. URL: https://www.semanticscholar.org/paper/25ce7638df4eed046342055c0c04363b8a434b29
[7] Cui, Q., Peng, L., Wei, L., Chang, J., Tan, W., Luo, Y., Huang, X., Zhao, Y., Li, J., Chu, J., Shao, M., Zhang, C., Li, C., Tan, W., Lin, D., & Wu, C. (2017). Genetic variant repressing ADH1A expression confers susceptibility to esophageal squamous-cell carcinoma. *Cancer Letters*. URL: https://www.semanticscholar.org/paper/497004ab5aaa6bd1581098efe5c63b9063caf436
[8] Huang, W., Yang, M., Wu, X., Yuan, L., Wu, Y., Hwang, J., Guan, J., & Liu, L. (2020). Expression profile and